spacer
home > ebr > spring 2019 > a new class of innovation
PUBLICATIONS
European Biopharmaceutical Review

A New Class of Innovation

EBR: What promise do advanced therapy medicinal products (ATMPs) offer in terms of treatment?

ATMPs are a rapidly growing, diverse variety of technologies covering a various range of therapeutic areas. The technologies include:

• Autologous cell therapies: Cells removed from a patient, processed in some way, and returned to the same patient
• Allogeneic cell therapies: Cells capable of being banked and can be administered to multiple patients after processing
• Ex vivo gene therapies: Autologous or allogeneic cell therapies which are genetically modified as part of the Good Manufacturing Practice process (to correct a faulty gene or target the cell in a predetermined way to, for example, attack a tumour) prior to being returned to the patient
• In vivo gene therapies: Direct injection of a viral or nonviral delivery system which will correct one or more faulty genes in the body

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Angela Osborne is Managing Director at eXmoor Pharma Concepts, which she founded in 2004. Angela has a BSc and PhD in biochemical engineering from University College London, UK, and over 30 years’ experience in biopharmaceutical and cell and gene therapy businesses, processes, and facilities. Her previous roles include Senior Vice President of Pharmaceuticals at Aker Kvaerner and Group Leader of Process Engineering at British Biotech. eXmoor is now a globally recognised biopharmaceutical and cell and gene therapy manufacturing consultancy that has completed more than 300 projects across 12 countries. Angela is also a member of the BioIndustry's Association Cell Therapy Industry Group Advisory Committee and the Manufacturing Advisory Committee as well as the co-founder of the ATMP Manufacturing Community.
spacer
Dr Angela Osborne
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo sponsored the carriage of historical artifacts from the Topkapı and Dolmabahçe Palaces to Japan

Turkish Cargo, the air cargo brand of Turkish Airlines that provides service to 124 countries, carried 186 historical artifacts, owned by Dolmabahçe and Topkapı Palaces, to Tokyo, the capital of Japan, as the sponsor carrier, in order to be displayed at the exhibition titled as "The Ottoman Empire and Tulip Culture" held as part of the events organized for 2019 which was declared as the "Year of Turkish Culture" across Japan.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement